189 related articles for article (PubMed ID: 38156860)
21. Richter transformation - retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group.
Sośnia O; Pruszczyk K; Danecki M; Wąsik-Szczepanek E; Tryc-Szponder J; Iskierka-Jażdżewska E; Majeranowski A; Krzemień H; Bołkun Ł; Paszkiewicz-Kozik E; Drozd-Sokołowska J; Kwiatkowski J; Wiśniewska-Organek D; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Budziszewska B; Jamroziak K; Hus I; Lech-Marańda E; Puła B
Leuk Lymphoma; 2024 Feb; 65(2):175-186. PubMed ID: 37921067
[TBL] [Abstract][Full Text] [Related]
22. Frequent expression of PD-L1 in BLS-type diffuse large B-cell lymphoma: implications for aggressiveness and immunotherapy.
Yang CF; Yu YT; Wang SH; Chen YP; Chen TY; Hsu CY; Medeiros LJ; Chang KC
Pathology; 2024 Apr; 56(3):367-373. PubMed ID: 38290893
[TBL] [Abstract][Full Text] [Related]
23. TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas: Implications for Targeted Therapy.
Libert D; Zhao S; Younes S; Mosquera AP; Bharadwaj S; Ferreira C; Natkunam Y
Am J Surg Pathol; 2024 Mar; 48(3):337-352. PubMed ID: 38148663
[TBL] [Abstract][Full Text] [Related]
24. PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.
Li L; Sun R; Miao Y; Tran T; Adams L; Roscoe N; Xu B; Manyam GC; Tan X; Zhang H; Xiao M; Tzankov A; Visco C; Dybkaer K; Bhagat G; Tam W; Hsi ED; van Krieken JH; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Zhang M; Winter JN; Medeiros LJ; Rassidakis GZ; Vaupel CA; Li Y; Dakappagari N; Xu-Monette ZY; Young KH
Mod Pathol; 2019 Jun; 32(6):741-754. PubMed ID: 30666052
[TBL] [Abstract][Full Text] [Related]
25. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
Xing W; Dresser K; Zhang R; Evens AM; Yu H; Woda BA; Chen BJ
Oncotarget; 2016 Sep; 7(37):59976-59986. PubMed ID: 27527850
[TBL] [Abstract][Full Text] [Related]
27. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
[TBL] [Abstract][Full Text] [Related]
28. PD-1 expression on tumour-infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B-cell lymphoma.
Wada F; Kamijo K; Shimomura Y; Yamashita D; Hara S; Ishikawa T
Immunology; 2024 Feb; 171(2):224-234. PubMed ID: 37904615
[TBL] [Abstract][Full Text] [Related]
29. Sentinel case of Richter transformation from chronic lymphocytic leukaemia/small lymphocytic lymphoma to CD3+ diffuse large B-cell lymphoma.
Ismail A; Mallick JA; Qin D; Hussaini MO
J Clin Pathol; 2017 Jul; 70(7):575-578. PubMed ID: 27899414
[TBL] [Abstract][Full Text] [Related]
30. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
Mao Z; Quintanilla-Martinez L; Raffeld M; Richter M; Krugmann J; Burek C; Hartmann E; Rudiger T; Jaffe ES; Müller-Hermelink HK; Ott G; Fend F; Rosenwald A
Am J Surg Pathol; 2007 Oct; 31(10):1605-14. PubMed ID: 17895764
[TBL] [Abstract][Full Text] [Related]
31. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
Ding W; LaPlant BR; Call TG; Parikh SA; Leis JF; He R; Shanafelt TD; Sinha S; Le-Rademacher J; Feldman AL; Habermann TM; Witzig TE; Wiseman GA; Lin Y; Asmus E; Nowakowski GS; Conte MJ; Bowen DA; Aitken CN; Van Dyke DL; Greipp PT; Liu X; Wu X; Zhang H; Secreto CR; Tian S; Braggio E; Wellik LE; Micallef I; Viswanatha DS; Yan H; Chanan-Khan AA; Kay NE; Dong H; Ansell SM
Blood; 2017 Jun; 129(26):3419-3427. PubMed ID: 28424162
[TBL] [Abstract][Full Text] [Related]
32. Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop.
Czader M; Amador C; Cook JR; Thakkar D; Parker C; Dave SS; Dogan A; Duffield AS; Nejati R; Ott G; Xiao W; Wasik M; Goodlad JR
Am J Clin Pathol; 2023 Jun; 159(6):554-571. PubMed ID: 37052539
[TBL] [Abstract][Full Text] [Related]
33. Hodgkin lymphoma transformation of chronic lymphocytic leukemia-A real life data from the Polish Lymphoma Research Group.
Drozd-Sokołowska J; Zaucha JM; Żółtak T; Jamroziak K; Grzybowska-Izydorczyk O; Witkowska M; Waszczuk-Gajda A; Kaźmierczak M; Szczepaniak A; Subocz E; Knopińska-Posłuszny W; Hołojda J; Kopińska A; Hus I; Rybka J; Wołowiec D; Kwiatkowski J; Hałaburda K; Smolewski P; Giebel S; Wiktor-Jędrzejczak W
Hematol Oncol; 2019 Oct; 37(4):383-391. PubMed ID: 31026087
[TBL] [Abstract][Full Text] [Related]
34. Expression of AIF and HtrA2/Omi in small lymphocytic lymphoma and diffuse large B-cell lymphoma.
Li S; Wan M; Cao X; Ren Y
Arch Pathol Lab Med; 2011 Jul; 135(7):903-8. PubMed ID: 21732781
[TBL] [Abstract][Full Text] [Related]
35. The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified.
Slak TC; Miceska S; Gasljevic G; Boltezar L; Kloboves-Prevodnik V
Radiol Oncol; 2024 Mar; 58(1):99-109. PubMed ID: 38378036
[TBL] [Abstract][Full Text] [Related]
36. Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy.
Jamroziak K; Tadmor T; Robak T; Polliack A
Leuk Lymphoma; 2015 Jul; 56(7):1949-58. PubMed ID: 25356923
[TBL] [Abstract][Full Text] [Related]
37. Angioimmunoblastic T-Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Novel Form of Composite Lymphoma Potentially Mimicking Richter Syndrome.
Trimech M; Letourneau A; Missiaglia E; De Prijck B; Nagy-Hulliger M; Somja J; Vivario M; Gaulard P; Lambert F; Bisig B; de Leval L
Am J Surg Pathol; 2021 Jun; 45(6):773-786. PubMed ID: 33739791
[TBL] [Abstract][Full Text] [Related]
38. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.
Jain N; Senapati J; Thakral B; Ferrajoli A; Thompson P; Burger J; Basu S; Kadia T; Daver N; Borthakur G; Konopleva M; Pemmaraju N; Parry E; Wu CJ; Khoury J; Bueso-Ramos C; Garg N; Wang X; Lopez W; Ayala A; O'Brien S; Kantarjian H; Keating M; Allison J; Sharma P; Wierda W
Blood Adv; 2023 May; 7(10):1958-1966. PubMed ID: 36287248
[TBL] [Abstract][Full Text] [Related]
39. Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.
García-Barchino MJ; Sarasquete ME; Panizo C; Morscio J; Martinez A; Alcoceba M; Fresquet V; Gonzalez-Farre B; Paiva B; Young KH; Robles EF; Roa S; Celay J; Larrayoz M; Rossi D; Gaidano G; Montes-Moreno S; Piris MA; Balanzategui A; Jimenez C; Rodriguez I; Calasanz MJ; Larrayoz MJ; Segura V; Garcia-Muñoz R; Rabasa MP; Yi S; Li J; Zhang M; Xu-Monette ZY; Puig-Moron N; Orfao A; Böttcher S; Hernandez-Rivas JM; Miguel JS; Prosper F; Tousseyn T; Sagaert X; Gonzalez M; Martinez-Climent JA
J Pathol; 2018 May; 245(1):61-73. PubMed ID: 29464716
[TBL] [Abstract][Full Text] [Related]
40. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
